Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders

Area of Science:

• Immunology
• Neuroimmunology
• Autoimmunity

Background:

• B cells differentiate into short-lived plasmablasts (SLPBs) and long-lived plasma cells (LLPCs).
• IgG4 antibodies, driven by Th2 responses, can cause autoimmune disorders by disrupting ligand-receptor binding.
• IgG4-mediated disorders, like myasthenia gravis, often show long-term remission after B cell depletion, indicating short-lived antibody-secreting cells.

Purpose of the Study:

• To review the short- and long-lived nature of antibody-secreting cells (ASCs) in IgG1 and IgG4 autoantibody-mediated neurological disorders.
• To highlight common mechanisms and differences in ASC longevity between IgG1 and IgG4 autoimmunity.
• To inform therapeutic strategies and personalized medicine for these conditions.

Main Methods:

• Review of existing literature on ASCs in IgG1 and IgG4 autoimmune neurological disorders.
• Analysis of clinical responses to B cell depletion therapies (e.g., rituximab).
• Comparison of factors influencing ASC longevity, including germinal center involvement.

Main Results:

• IgG4 autoantibody-mediated disorders frequently exhibit short-lived ASCs, leading to sustained remission post-rituximab treatment.
• IgG1 autoantibody disorders may involve LLPCs, potentially due to germinal center-like structures, resulting in less durable remissions.
• Differences in ASC longevity impact treatment outcomes and the potential for refractory disease.

Conclusions:

• The lifespan of ASCs differs significantly between IgG1 and IgG4 autoantibody-mediated disorders.
• Understanding ASC kinetics is crucial for developing effective and personalized therapeutic strategies.
• Targeting B cell populations may be more effective for IgG4-driven conditions due to the short-lived nature of ASCs.